Chongqing Land Tower

Chongqing Land Tower Pharmaceutical is a clinical-stage biopharmaceutical company based in Chongqing, China, dedicated to the research, development, and commercialization of innovative biologics and high-end biosimilars. The company primarily targets metabolic disorders, including osteoporosis and type 2 diabetes, as well as various oncological indications. Its most advanced program, LT-002, is a denosumab biosimilar currently undergoing Phase 3 clinical trials for postmenopausal osteoporosis. Additionally, the company is developing LT-102, a dual GLP-1/GIP receptor agonist for obesity and diabetes, and LT-001, a teriparatide biosimilar. Chongqing Land Tower operates a comprehensive R&D and manufacturing facility designed to meet international GMP standards. Through its focus on high-barrier biological drugs, the company aims to improve patient access to life-changing therapies in China and global markets.